although
effect
use
highli
activ
antiretrovir
therapi
result
suppress
viru
product
infect
individu
elimin
infect
low
level
viru
product
cell
harbor
viru
sanctuari
site
thu
continu
search
new
antiretrovir
agent
uniqu
differ
mechan
hiv
inhibit
remain
critic
compound
reduc
level
viru
product
cell
alreadi
infect
hiv
oppos
prevent
de
novo
infect
would
great
benefit
mercaptobenzamid
prodrug
develop
potenti
therapeut
compound
target
zinc
finger
hiv
nucleocapsid
presenc
esteras
enzym
design
convert
antivir
activ
presum
rapidli
convert
experi
two
compound
test
sidebysid
determin
whether
presenc
prodrug
affect
antivir
activ
mechan
action
two
compound
evalu
panel
clinic
isol
human
pbmc
monocytemacrophag
yield
ec
valu
rang
mm
toxic
mm
remain
equal
activ
human
pbmc
presenc
ad
serum
protein
well
isol
resist
revers
transcriptas
integras
proteas
inhibitor
cellbas
biochem
mechan
antivir
action
assay
demonstr
virucid
concentr
mm
respect
cell
cell
transmiss
hiv
multipl
passag
significantli
reduc
cemss
human
pbmc
reduc
progeni
viru
infect
compound
concentr
greater
mm
combin
either
fdaapprov
hiv
drug
yield
addit
synergist
antivir
interact
evid
antivir
antagon
synergist
toxic
serial
dose
escal
use
attempt
select
hiv
strain
resist
viru
sever
passag
fail
replic
cell
treat
increas
compound
concentr
consist
propos
mechan
action
viru
inactiv
compound
passag
resist
compound
achiev
hiv
inhibitor
mechan
antivir
action
target
viral
protein
would
select
drug
resist
viru
within
passag
studi
indic
compound
repres
new
potent
antihiv
drug
candid
could
effect
use
combin
approv
antihiv
drug
fixeddos
combin
antiretrovir
therapi
reduc
aidsassoci
morbid
mortal
patient
infect
due
excel
efficaci
toler
despit
develop
highli
effect
antiretrovir
agent
arv
therapi
erad
hiv
infect
lifelong
treatment
necessari
berg
cours
longterm
treatment
emerg
drugresist
hiv
reduc
effect
antiretrovir
therapi
threaten
virolog
suppress
hiv
develop
novel
therapeut
high
genet
barrier
hiv
resist
low
toxic
thu
remain
necess
develop
specif
virucid
compound
abil
interfer
multipl
stage
hiv
replic
potenti
add
significantli
abil
treat
hiv
infect
nucleocapsid
protein
hiv
unexploit
target
disrupt
hiv
small
molecul
mori
et
al
establish
hiv
target
therapeut
applic
enzym
name
hiv
proteas
integras
revers
transcriptas
viral
entryfus
inhibitor
small
amino
acid
protein
contain
two
highli
conserv
zinc
finger
deriv
cysxaa
cysxaa
cchc
motif
main
role
bind
viral
rna
protect
degrad
covey
guo
et
al
ramboarina
et
al
tanchou
et
al
alter
one
zincchel
amino
acid
surround
amino
acid
result
product
noninfecti
viru
function
multipl
stage
hiv
replic
includ
revers
transcript
integr
tatpromot
transcript
autocatalysi
gagpol
precursor
form
function
proteas
promot
gag
assembl
interact
viral
genom
rna
protect
doublestrand
hiv
genom
rna
degrad
buckman
et
al
guo
et
al
hargittai
et
al
turpin
et
al
zybarth
carter
berkowitz
et
al
dawson
yu
shubsda
et
al
lapadattapolski
et
al
mechanist
activ
suggest
potenti
high
genet
barrier
select
resist
suggest
resist
strain
may
emerg
might
suffer
signific
loss
fit
vitro
evalu
confirm
remov
zinc
zinc
finger
result
loss
viral
infect
impair
revers
transcript
defect
gagprecursor
matur
sinc
discoveri
inhibitor
attack
zinc
finger
varieti
class
inhibitor
describ
rice
et
al
ryser
et
al
turpin
et
al
sancineto
et
al
kim
et
al
mani
describ
recent
review
mori
et
al
inhibitor
act
coval
modif
target
although
molecul
typic
lead
undesir
toxic
recent
report
use
diselenobisbenzamid
inhibit
hiv
replic
via
coval
modif
promis
new
develop
area
sancineto
et
al
anoth
strategi
inhibit
screen
noncoval
inhibitor
recent
success
area
identifi
compound
base
rhodanin
core
structur
kim
et
al
entir
collect
inhibitor
howev
ec
valu
antivir
activ
hiv
low
micromolar
rang
compar
drug
use
treat
hiv
infect
antivir
activ
inhibitor
significantli
weaker
therefor
altern
strategi
target
consid
previous
identifi
specif
class
benzamid
thioester
nsubstitut
samt
fig
select
inactiv
exhibit
minim
vitro
cytotox
jenkin
et
al
loo
et
al
schito
et
al
srivastava
et
al
huang
et
al
rice
et
al
rice
et
al
rice
et
al
rice
et
al
samt
also
inhibit
hiv
replic
acut
chronic
hivinfect
cell
samt
specif
transfer
acetyl
group
cystein
transfer
intramolecularli
neighbor
lysin
side
chain
acetyl
samt
protein
lose
zinc
coordin
unfold
longer
function
support
hiv
replic
also
discov
acetyl
transfer
conjug
thiol
samt
reacetyl
via
pathway
involv
acetyl
coa
mechan
potenti
allow
samt
inactiv
multipl
copi
via
catalyt
mechan
shown
fig
howev
thioester
bond
samt
highli
suscept
hydrolysi
make
difficult
formul
therapeut
product
addit
studi
mechan
samt
determin
acetyl
group
need
part
molecul
time
deliveri
infect
cell
instead
treatment
conjug
thiol
samt
see
conjug
thiol
fig
suffici
achiev
antivir
activ
due
intracellular
activ
conjug
thiol
acetyl
coa
miller
jenkin
et
al
thiol
rel
stabl
solid
form
solut
slowli
oxid
form
disulfid
therefor
want
investig
whether
thiol
correspond
prodrug
would
avoid
oxid
solut
may
provid
easier
drug
formul
solut
design
samtbas
therapi
treat
hiv
infect
manuscript
demonstr
sacetyl
portion
samt
remov
formul
still
retain
benefici
antivir
activ
regard
prodrug
evalu
investig
potenti
antivir
agent
includ
antivir
efficaci
cellular
toxic
mechan
antivir
activ
presenc
esteras
enzym
rapidli
convert
fig
preclin
toxic
pharmacokinet
properti
also
evalu
rat
unless
otherwis
state
reaction
carri
atmospher
nitrogen
solvent
purifi
j
c
meyer
glass
contour
solvent
system
reagent
purchas
sigma
aldrich
st
loui
mo
use
receiv
balanin
amid
hydrochlorid
purchas
pharmaron
beij
china
use
receiv
nmr
spectra
obtain
room
temperatur
bruker
ultrashield
plu
signal
report
ppm
multipl
number
proton
mass
spectra
record
water
lct
premier
report
thiosalicyl
acid
g
mmol
eq
combin
balanin
amid
hydrochlorid
g
mmol
eq
hctu
g
mmol
eq
ml
dmf
room
temperatur
mixtur
stir
min
base
ad
drop
wise
ml
stir
overnight
major
solvent
remov
vacuum
result
residu
pour
ml
crush
icewat
mixtur
left
open
air
stir
vigor
overnight
result
precipit
isol
filtrat
sticki
filter
cake
wash
repeatedli
ml
portion
water
isol
spatula
dri
vacuo
give
g
yield
white
solid
suffici
puriti
use
next
step
round
bottom
flask
charg
g
mmol
eq
tcep
hydrochlorid
g
mmol
eq
dmfwater
ad
ml
follow
base
ml
mmol
eq
mixtur
stir
overnight
room
temperatur
roughli
half
solvent
remov
vacuo
residu
treat
ml
water
mixtur
place
refriger
overnight
form
white
precipit
result
solid
isol
filtrat
sticki
filter
cake
wash
repeatedli
ml
portion
water
isol
spatula
vacuum
dri
give
g
offwhit
solid
yield
h
nmr
mhz
dmsod
dd
dd
bs
td
td
bs
bs
c
nmr
mhz
dmsod
hrm
esi
mz
calcd
c
h
n
found
round
bottom
flask
ad
thiosalicyl
acid
g
mmol
eq
hbtu
g
mmol
eq
balanin
amid
hydrochlorid
g
mmol
eq
dmf
ml
ad
follow
base
ml
mmol
eq
mixtur
stir
rt
h
chloromethyl
butyr
ml
mmol
eq
inject
reaction
stir
h
rt
reaction
quench
water
ml
extract
ml
ch
cl
combin
organ
wash
satur
nahco
brine
dri
na
organ
evapor
residu
purifi
flash
chromatographi
silica
gel
meohdcm
yield
g
yield
white
solid
mercaptobenzamid
prodrug
provid
niddknih
control
compound
either
purchas
sigma
aldrich
st
loui
mo
obtain
niaid
aid
research
refer
reagent
program
germantown
md
establish
cell
line
hiv
strain
obtain
niaid
aid
research
refer
reagent
program
rockvil
md
peripher
blood
mononuclear
cell
pbmc
isol
ficol
hypaqu
gradient
centrifug
whole
blood
biolog
specialti
corpor
colmar
pa
activ
pha
monocyt
purifi
adher
plastic
wash
remov
lymphocyt
follow
seven
day
acut
infect
clinic
wild
type
drug
resist
hiv
isol
presenc
compound
supernat
revers
transcriptas
rt
activ
express
elisa
measur
quantifi
viru
replic
buckheit
et
al
buckheit
et
al
cell
viabil
measur
parallel
use
xtt
dye
reduct
test
compound
ad
tzmblfcri
cell
plate
flatbottom
plate
h
prior
assay
initi
buckheit
et
al
buckheit
et
al
predetermin
titer
viru
ad
min
follow
cell
pretreat
test
compound
co
incub
addit
h
end
incub
residu
viru
compound
remov
wash
fresh
media
ad
cultur
incub
addit
h
begalactosidas
express
determin
chemiluminesc
efficaci
plate
tropix
bedford
mass
compound
incub
cell
flatbottom
plate
h
cocultur
cell
h
buckheit
et
al
buckheit
et
al
follow
incub
cell
lyse
evalu
b
galactosidas
express
use
galscreen
biochem
rt
inhibit
assay
util
recombin
purifi
rt
enzym
buckheit
et
al
buckheit
et
al
rt
enzym
assay
ml
reaction
mixtur
contain
mm
trishcl
ph
mm
kcl
mm
mgcl
mm
dtt
mm
dgtp
rc
dg
templat
primer
amersham
pharmacia
biotech
piscataway
nj
mci
p
adgtp
cimmol
test
compound
enzym
reaction
allow
proceed
min
c
termin
reaction
addit
tca
mg
heatdenatur
sonic
salmon
sperm
dna
ad
aid
dna
precipit
recoveri
tcaprecipit
dna
harvest
onto
glassfib
filter
wash
twice
icecold
tca
subject
liquid
scintil
count
incorpor
radioact
label
dna
sampl
quantifi
use
wallac
microbeta
scintil
counter
integras
assay
kit
bioproduct
md
middletown
md
use
examin
integras
inhibit
activ
buckheit
et
al
buckheit
et
al
plate
coat
doublestrand
ltr
donor
substrat
ds
oligonucleotid
contain
endlabel
biotin
fulllength
recombin
integras
protein
ad
follow
test
articl
differ
doublestrand
target
substrat
ts
oligo
contain
modif
product
reaction
detect
colorimetr
use
hrplabel
antibodi
direct
ts
modif
sensolyt
proteas
assay
kit
anaspec
inc
san
jose
ca
recombin
proteas
use
examin
proteas
inhibit
activ
buckheit
et
al
buckheit
et
al
cleavag
junction
proteas
proteas
activ
presenc
test
compound
monitor
fluoresc
plate
reader
use
excit
emiss
wavelength
nm
compound
incub
undilut
hiv
iiib
min
c
buckheit
et
al
buckheit
et
al
follow
incub
tube
centrifug
rpm
c
min
wash
five
time
tissu
cultur
medium
viru
pellet
resuspend
rpmi
medium
predetermin
titer
untreat
viru
incub
cemss
cell
day
co
quantifi
effect
compound
treatment
viru
infect
cell
viabil
measur
xtt
tetrazolium
dye
hivinfect
fresh
human
pbmc
treat
six
concentr
test
compound
three
day
cultur
passag
presenc
fix
concentr
compound
replac
cultur
volum
fresh
compoundcontain
medium
uninfect
cell
everi
day
three
passag
buckheit
et
al
buckheit
et
al
cellfre
supernat
sampl
collect
day
subcultur
defin
level
viru
replic
occur
presenc
fix
concentr
test
compound
rt
extracellular
antigen
measur
tcid
valu
passag
determin
endpoint
dilut
efficaci
toxic
compound
alon
combin
analyz
microtit
plate
base
pbmc
assay
describ
use
inhous
softwar
program
calcul
cpe
reduct
reduct
viru
replic
cell
viabil
ec
ec
ec
tc
tc
tc
select
indic
display
result
graphic
hartman
et
al
combin
antivir
effect
efficaci
toxic
analyz
statist
prichard
shipman
macsynergi
ii
methodolog
macsyneri
ii
analysi
includ
calcul
dose
respons
two
compound
use
alon
follow
calcul
expect
addit
level
antivir
inhibit
compound
use
togeth
base
individu
dose
respons
curv
expect
level
activ
concentr
data
point
compar
experiment
determin
antivir
activ
assay
expect
activ
subtract
realiz
activ
yield
neg
zero
posit
valu
valu
plot
yield
threedimension
represent
data
zero
valu
indic
expect
realiz
activ
yield
flat
surfac
indic
addit
interact
two
compound
posit
valu
indic
realiz
activ
greater
expect
activ
thu
potenti
synergist
interact
compound
observ
assay
accumul
posit
point
synergi
plot
yield
threedimension
surfac
project
plane
addit
volum
surfac
plane
calcul
express
unit
mm
macsynergi
ii
contrast
neg
valu
indic
realiz
activ
less
expect
activ
yield
surfac
project
plane
addit
indic
antagonist
interact
compound
extens
experi
evalu
combin
assay
data
result
follow
interpret
synergi
volum
deriv
macsynergi
ii
data
mm
defin
highli
synergist
interact
mm
defin
synergist
mm
mm
defin
addit
mm
defin
antagonist
mm
defin
highli
antagonist
serial
dose
escal
method
resist
select
util
cemss
cell
laboratoryderiv
iiib
viru
strain
buckheit
et
al
method
perform
cultur
viru
presenc
suboptim
concentr
small
increas
drug
concentr
made
passag
gradual
increas
select
pressur
viru
replic
cell
viru
product
quantifi
rt
assay
determin
peak
day
viru
passag
titer
viru
harvest
peak
day
viru
product
sensit
select
control
compound
defin
passag
maximum
toler
dose
mtd
spraguedawley
rat
follow
dose
escal
design
vial
oral
administr
five
group
anim
femal
male
dose
vial
oral
administr
dose
level
mgkgdose
use
water
mgkgdose
use
cmcna
water
paramet
evalu
includ
cage
side
detail
clinic
observ
bodi
weight
food
consumpt
gener
procedur
anim
care
hous
conduct
accord
nation
research
council
care
use
laboratori
anim
anim
welfar
standard
code
feder
regul
procedur
protocol
use
describ
vivo
studi
review
approv
institut
anim
care
use
committe
perform
aaalac
accredit
facil
fourteenday
repeat
dose
toxic
evalu
daili
oral
administr
perform
thirtytwo
spraguedawley
rat
revers
progress
potenti
delay
effect
determin
follow
fourteenday
recoveri
period
four
group
anim
main
studi
anim
sacrif
day
recoveri
anim
sacrif
day
oral
dose
daili
basi
dose
level
mgkgdose
parallel
control
articl
blood
sampl
clinic
patholog
analys
collect
anim
prior
termin
sacrific
main
studi
anim
euthan
necropsi
day
recoveri
anim
euthan
necropsi
day
paramet
evalu
includ
cagesid
detail
clinic
observ
bodi
weight
food
consumpt
clinic
patholog
clinic
chemistri
hematolog
coagul
urinalysi
absolut
rel
organ
weight
gross
patholog
microscop
patholog
synthes
shown
scheme
molecul
made
start
thiosalicyl
acid
amid
coupl
hydrochlorid
salt
balanin
amid
thiosalicyl
acid
facilit
use
reagent
hctu
reaction
complet
standard
work
yield
disfulfid
yield
disulfid
reduc
use
tcep
yield
synthesi
prodrug
perform
twostep
singl
flask
without
isol
intermedi
perform
amid
bond
reaction
thiosalicyl
acid
balanin
amid
chloromethyl
butyr
ad
work
reaction
isol
yield
scheme
ensur
could
easili
convert
routin
metabolit
identif
studi
perform
vitro
use
human
plasma
support
inform
incub
h
human
plasma
clearli
identifi
along
minor
metabolit
addit
evid
convers
obtain
studi
vivo
pharmacokinet
rat
see
section
prodrug
evalu
parallel
azt
panel
low
passag
human
clinic
subtyp
virus
repres
group
subtyp
g
group
fresh
human
pbmc
determin
rang
antivir
activ
tabl
prodrug
evalu
parallel
azt
six
tropic
hiv
strain
fresh
human
monocyt
macrophag
tabl
yield
ec
valu
rang
mm
mm
respect
panel
hiv
strain
fresh
human
monocyt
macrophag
cytotox
fresh
human
monocytemacrophag
concentr
greater
mm
respect
prodrug
evalu
antivir
activ
assay
iiib
cemss
cell
clinic
subtyp
b
viru
fresh
human
pbmc
absenc
presenc
human
serum
mgml
alpha
scheme
synthesi
prodrug
glycoprotein
aagp
mgml
human
serum
albumin
hsa
determin
protein
bind
cell
cultur
data
shown
prodrug
perform
compar
cell
cultur
medium
presenc
aagp
ec
valu
rang
mm
compound
yield
approxim
decreas
potenc
presenc
human
ab
serum
also
yield
decreas
potenc
presenc
hsa
exhibit
signific
decreas
potenc
hsa
pbmc
prodrug
perform
compar
cell
cultur
medium
presenc
three
serum
protein
addit
signific
chang
antivir
activ
prodrug
evalu
parallel
posit
neg
control
compound
antivir
activ
assay
drugresist
wild
type
cell
tabl
prodrug
perform
compar
panel
drugresist
hiv
isol
ec
valu
rang
mm
mm
similar
activ
wild
type
hiv
prodrug
also
evalu
low
passag
human
clinic
virus
resist
known
antiretrovir
agent
fresh
human
pbmc
tabl
compound
perform
compar
panel
drug
resist
isol
exhibit
ec
valu
rang
mm
mm
similar
activ
seen
wild
type
hiv
isol
compound
found
nontox
cell
assay
high
test
concentr
mm
tabl
hiv
entri
fusion
inhibit
prodrug
evalu
abil
inhibit
hiv
attach
cell
express
cell
surfac
inhibit
cell
express
fuse
cell
chicago
sky
blue
enfuvirtid
evalu
posit
control
compound
yield
ec
valu
mgml
mm
respect
attach
inhibit
assay
fusion
inhibit
assi
yield
ec
valu
mm
attach
inhibit
assay
mm
fusion
inhibit
assay
inact
mm
attach
fusion
inhibit
assay
evalu
inhibit
wild
type
rt
biochem
rt
inhibit
assay
use
rc
dg
templat
primer
system
inhibit
hiv
rt
activ
evalu
concentr
mm
delavirdin
evalu
posit
control
compound
yield
ec
valu
mm
prodrug
evalu
abil
inhibit
hiv
integras
cleav
termin
two
base
expos
ltr
ds
catalyz
strandtransf
reaction
integr
doubl
strand
viral
dna
target
substrat
inhibit
hiv
integras
activ
evalu
concentr
mm
posit
control
compound
raltegravir
yield
ec
valu
mm
prodrug
evalu
abil
inhibit
hiv
proteas
cleavag
inhibit
hiv
proteas
activ
evalu
concentr
mm
saquinavir
evalu
posit
control
compound
yield
ec
valu
mm
prodrug
evalu
hiv
iiib
virucid
activ
fig
reduc
infect
hiv
virion
treat
min
wash
prior
infect
target
cemss
cell
concentr
mm
respect
posit
control
compound
zinc
finger
inhibitor
yield
ec
valu
mm
effect
viru
infect
hivinfect
cemss
cell
hivinfect
fresh
human
pbmc
evalu
three
passag
measur
hiv
transmiss
cell
cell
transmiss
hiv
iiib
three
consecut
passag
significantli
reduc
treatment
infect
cemss
cell
mm
measur
quantif
extracellular
viru
rt
assay
elisa
viru
infect
tcid
ml
tabl
prodrug
approxim
less
effect
reduc
cell
cell
hiv
transmiss
believ
fall
within
rang
error
particular
assay
fresh
human
pbmc
hiv
transmiss
use
clade
c
strain
similarli
reduc
mm
mm
follow
passag
measur
viru
quantif
use
rt
assay
elisa
well
viru
infect
measur
tcid
ml
tabl
saquinavir
evalu
parallel
posit
control
compound
cemss
pbmc
assay
signific
reduct
viru
replic
subsequ
infect
cemss
cell
pbmc
viru
treat
saquinavir
demonstr
prodrug
evalu
combin
twentythre
known
antihiv
agent
inhibit
cytopath
effect
cemss
cell
use
iiib
strain
data
shown
percent
viru
replic
inhibit
expect
concentr
twodrug
combin
calcul
confid
interv
importantli
combin
assay
demonstr
within
concentr
rang
employ
combin
antivir
assay
evid
either
antagon
synergist
toxic
observ
compound
combin
suggest
test
compound
could
safe
use
approv
inhibitor
yield
slightli
synergist
interact
cytoprotect
fusion
inhibitor
enfuviritid
mean
synergi
volum
mm
respect
combin
revers
transcriptas
inhibitor
yield
addit
synergist
interact
combin
delavirdin
efavirenz
nevirapin
zidovudin
tenofovir
stavudin
mean
synergi
volum
rang
mm
combin
lamivudin
stavudin
mean
synergi
volum
mm
respect
yield
synergist
interact
cytoprotect
combin
integras
inhibitor
dolutegravir
demonstr
synergist
interact
mean
synergi
volum
mm
combin
proteas
inhibitor
result
addit
highli
synergist
interact
combin
amprenavir
mean
synergi
volum
mm
respect
lopinavir
mean
synergi
volum
mm
respect
ritonavir
mean
synergi
volum
mm
respect
nelfinavir
mean
synergi
volum
mm
respect
result
synergist
highli
synergist
interact
cytoprotect
iiib
viru
propag
cemss
cell
presenc
increas
concentr
prodrug
peak
day
viru
replic
determin
revers
transcriptas
activ
use
evalu
compound
suscept
passag
foldincreas
ec
valu
compar
wild
type
viru
suscept
result
necessari
escal
dose
slight
increment
increas
concentr
follow
first
viru
passag
larger
volum
compoundtr
viru
need
consecut
acut
infect
compar
wild
type
viru
viru
growth
presenc
significantli
impair
compar
wild
type
hiv
made
viru
passag
difficult
presenc
increas
concentr
attempt
grow
viru
presenc
fix
high
concentr
compound
sever
passag
also
made
effort
select
drugresist
viru
fourteen
passag
hiv
presenc
result
resist
examin
toxic
vivo
standard
vitro
toxic
test
perform
test
inhibit
cytochrom
enzym
neither
signific
inhibitori
activ
standard
herg
test
cardiotox
also
neg
determin
toxic
vivo
toxic
spraguedawley
rat
examin
determin
maximum
toler
dose
mtd
singl
oral
administr
examin
repeat
dose
toxic
daili
oral
administr
consecut
day
administ
oral
gavag
suspens
carboxymethyl
cellulos
cmcna
water
suspens
vortex
sonic
obtain
homogen
solut
prior
administr
mtd
studi
dose
mgkg
deliv
dose
volum
mlkg
dose
mgkg
deliv
dose
volum
mlkg
account
increas
viscos
higher
dose
possibl
due
ethic
limit
quantiti
test
articl
reason
administ
evalu
toxic
dose
fourday
observ
period
examin
cagesid
clinic
observ
bodi
weight
food
consumpt
remark
exhibit
toxic
dose
mtd
studi
repeat
dose
toxic
studi
administ
formul
dose
mg
kg
consecut
day
anim
separ
main
group
sacrif
day
studi
recoveri
group
sacrif
day
studi
cagesid
clinic
observ
bodi
weight
food
consumpt
monitor
clinic
patholog
also
examin
anim
sacrif
across
paramet
toxic
observ
higher
dose
cloudi
urin
sampl
note
rat
howev
observ
correl
abnorm
kidneyrel
clinic
chemistri
histopatholog
chang
urinari
system
minor
observ
document
none
consid
signific
toxicolog
find
directli
relat
pharmacokinet
pk
profil
activ
metabolit
determin
male
spraguedawley
rat
n
singl
intraven
iv
oral
gavag
po
administr
administr
mgkg
iv
bolu
inject
mgml
solut
dmso
salin
mgkg
po
mgml
carboxymethyl
cellulos
cmc
suspens
blood
sampl
collect
predetermin
time
period
prevent
convers
sampl
collect
ml
blood
aliquot
tube
contain
ml
sodium
fluorid
ml
citric
acid
blood
sampl
kept
wet
ice
less
min
centrifug
c
harvest
plasma
plasma
sampl
store
c
analysi
plasma
sampl
analyz
ultraperform
liquid
chromatographytandem
mass
spectrometri
uplcmsm
method
iv
po
administr
rapidli
convert
esteras
blood
tissu
concentr
lower
limit
quantit
ngml
h
post
iv
dose
h
post
po
dose
areaundertheplasma
concentrationetim
curv
auc
ng
hml
ng
hml
iv
po
respect
auc
ng
hml
ng
hml
iv
po
administr
respect
tabl
pk
profil
mgkg
iv
mgkg
po
administr
depict
fig
molecul
submit
divis
microbiolog
infecti
diseas
dmid
antivir
screen
program
within
nation
institut
allergi
infecti
diseas
niaid
molecul
fail
show
activ
influenza
viru
type
respiratori
syncyti
viru
venezuelan
equin
enceph
viru
weak
activ
ec
mm
rift
valley
fever
viru
sar
corona
viru
tacarib
viru
ebola
viru
prodrug
develop
potenti
therapeut
compound
target
zinc
finger
nucleocapsid
compound
similarli
broadli
activ
geograph
divers
panel
clinic
subtyp
inhibit
dualtrop
viru
strain
equal
efficaci
prodrug
equal
activ
monocytetrop
strain
fresh
human
monocyt
data
demonstr
prodrug
would
expect
activ
strain
found
throughout
world
therapeut
product
lack
cross
resist
hiv
strain
confer
resist
revers
transcriptas
inhibitor
integras
inhibitor
proteas
inhibitor
well
multidrug
resist
isol
indic
distinct
mechan
antivir
action
prodrug
compar
approv
hiv
drug
follow
cellbas
biochem
inhibit
assay
evalu
mechan
antivir
action
conclud
prodrug
act
virucid
agent
reduc
transmiss
infecti
viru
multipl
round
viru
replic
reduct
viru
infect
prove
challeng
passag
viru
presenc
attempt
select
drug
resist
hiv
viru
cultur
presenc
increas
concentr
fourteen
passag
presenc
result
resist
uniqu
compar
hiv
inhibitor
reduc
viru
replic
target
viral
protein
combin
assay
perform
repres
variou
class
hiv
inhibitor
prodrug
result
addit
synergist
interact
approv
inhibitor
greatest
level
synergi
observ
compound
inhibit
proteas
ritonavir
lopinavir
nelfinavir
importantli
signific
combin
antagon
synergist
toxic
combin
therapi
assay
concentr
test
evalu
vivo
toxic
rat
show
nontox
even
dose
mgkg
repeat
consecut
day
detail
pharmacokinet
analysi
show
rapidli
break
blood
subsequ
studi
underway
character
metabolit
studi
indic
compound
repres
new
potent
antihiv
drug
candid
could
safe
effect
use
combin
approv
antihiv
drug
